Malignant pleural mesothelioma: medical treatment update

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Background:

• Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer with limited treatment efficacy.
• Systemic chemotherapy remains the primary therapeutic option for most MPM patients.
• Few therapeutic strategies have shown significant impact on MPM outcomes.

Purpose of the Study:

• To review the current landscape of systemic chemotherapeutic drugs for malignant pleural mesothelioma.
• To highlight the established standard of care and emerging targeted therapies for MPM.
• To provide an overview of clinical trials investigating novel MPM treatments.

Main Methods:

• Review of phase II and phase III clinical trials.
• Analysis of various chemotherapeutic agents including anthracyclines, alkylating agents, platinum compounds, taxanes, vinka alkaloids, and antifolates.
• Identification of the current standard of care regimen.

Main Results:

• The combination of pemetrexed and cisplatin has emerged as the current standard of care based on large-scale clinical trials.
• Extensive research has explored numerous single-agent and combination chemotherapies.
• New targeted therapeutic approaches are under investigation globally.

Conclusions:

• Systemic chemotherapy, particularly the pemetrexed-cisplatin combination, is the cornerstone of malignant pleural mesothelioma treatment.
• Ongoing research focuses on novel targeted therapies to improve patient response and survival.
• Further clinical trials are essential to advance MPM therapeutic strategies.